Literature DB >> 17267537

Erythropoietin and its lost receptor.

Alessio Sturiale, Susanna Campo, Eleonora Crascì, Giuseppe Coppolino, Davide Bolignano, Giovanni Grasso, Michele Buemi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17267537     DOI： 10.1093/ndt/gfl769

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  4 in total

1.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

2.  Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.

Authors:  Scott D Patterson; John M Rossi; Katherine L Paweletz; V Dan Fitzpatrick; C Glenn Begley; Leigh Busse; Steve Elliott; Ian McCaffery
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

3.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

4.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.